Literature DB >> 19525472

Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.

Yusuf Menda1, Laura L Boles Ponto, Kenneth J Dornfeld, Timothy J Tewson, G Leonard Watkins, Michael K Schultz, John J Sunderland, Michael M Graham, John M Buatti.   

Abstract

UNLABELLED: The purpose of this study was to investigate the kinetic behavior of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) before and early after initiation of chemoradiation therapy in patients with squamous cell head and neck cancer.
METHODS: A total of 8 patients with head and neck cancer underwent (18)F-FLT PET scans (7 patients at baseline and after 5 d [10 Gy] of radiation therapy given with concomitant chemotherapy and 1 patient only at baseline). Dynamic PET images were obtained with concurrent arterial or venous blood sampling. Kinetic parameters including the flux constant of (18)F-FLT based on compartmental analysis (K-FLT), the Patlak influx constant (K-Patlak), and standardized uptake value (SUV) were calculated for the primary tumor and (18)F-FLT-avid cervical lymph nodes for all scans.
RESULTS: Mean pretreatment values of uptake for the primary tumor and cervical nodes were 0.075 +/- 0.006 min(-1), 0.042 +/- 0.004 min(-1), and 3.4 +/- 0.5 (mean +/- SD) for K-FLT, K-Patlak, and SUV, respectively. After 10 Gy of radiation therapy, these values were 0.040 +/- 0.01 min(-1), 0.018 +/- 0.016 min(-1), and 1.8 +/- 1.1 for K-FLT, K-Patlak, and SUV, respectively. For all lesions seen on pretherapy and midtherapy scans, the correlation was 0.90 between K-FLT and K-Patlak, 0.91 between K-FLT and SUV, and 0.99 between K-Patlak and SUV.
CONCLUSION: The initial (18)F-FLT uptake and change early after treatment in squamous head and neck tumors can be adequately characterized with SUV obtained at 45-60 min, which demonstrates excellent correlation with influx parameters obtained from compartmental and Patlak analyses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525472      PMCID: PMC2745313          DOI: 10.2967/jnumed.108.058495

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  20 in total

1.  Regulation by ionizing radiation of CDC2, cyclin A, cyclin B, thymidine kinase, topoisomerase IIalpha, and RAD51 expression in normal human diploid fibroblasts is dependent on p53/p21Waf1.

Authors:  S M de Toledo; E I Azzam; P Keng; S Laffrenier; J B Little
Journal:  Cell Growth Differ       Date:  1998-11

2.  Cell kinetic changes in human squamous cell carcinomas during radiotherapy studied using the in vivo administration of two halogenated pyrimidines.

Authors:  B Zackrisson; P Flygare; H Gustafsson; B Sjöström; G D Wilson
Journal:  Eur J Cancer       Date:  2002-05       Impact factor: 9.162

3.  Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma?

Authors:  G Valente; R Orecchia; S Gandolfo; M Arnaudo; R Ragona; S Kerim; G Palestro
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

4.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

5.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.

Authors:  Hubert Vesselle; John Grierson; Mark Muzi; Jeffrey M Pugsley; Rodney A Schmidt; Peter Rabinowitz; Lanell M Peterson; Eric Vallières; Douglas E Wood
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

6.  Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.

Authors:  Mark Muzi; Hubert Vesselle; John R Grierson; David A Mankoff; Rodney A Schmidt; Lanell Peterson; Joanne M Wells; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

7.  Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.

Authors:  Aren van Waarde; David C P Cobben; Albert J H Suurmeijer; Bram Maas; Willem Vaalburg; Erik F J de Vries; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

Review 8.  Imaging of cell proliferation: status and prospects.

Authors:  James R Bading; Anthony F Shields
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

9.  Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer.

Authors:  D Visvikis; D Francis; R Mulligan; D C Costa; I Croasdale; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

10.  18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.

Authors:  David C P Cobben; Bernard F A M van der Laan; Bram Maas; Willem Vaalburg; Albert J H Suurmeijer; Harald J Hoekstra; Pieter L Jager; Philip H Elsinga
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

View more
  31 in total

1.  Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer.

Authors:  Yusuf Menda; Laura L Boles Ponto; Kenneth J Dornfeld; Timothy J Tewson; G Leonard Watkins; Anjali K Gupta; Carryn Anderson; Sarah McGuire; Michael K Schultz; John J Sunderland; Michael M Graham; John M Buatti
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

2.  Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Megumi Jinguji; Nobuaki Nishimata; Shunji Shimaoka; Tohru Nihara; Kuniaki Aridome; Sadao Tanaka; Yoshihiko Fukukura; Atushi Tani; Chihaya Koriyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

3.  FDG-PET, a Complementary Modality to Computed-Tomography in Radiotherapy Target Volume Delineation for Head and Neck Cancer.

Authors:  Voichita Bar-Ad; Wenyin Shi; Madalina Tuluc; Nitin Ohri; David Cognetti; Joseph Curry; Charles Intenso
Journal:  J Nucl Med Radiat Ther       Date:  2012-02-01

4.  Heterogeneity in stabilization phenomena in FLT PET images of canines.

Authors:  Urban Simoncic; Robert Jeraj
Journal:  Phys Med Biol       Date:  2014-11-26       Impact factor: 3.609

Review 5.  PET imaging biomarkers in head and neck cancer.

Authors:  Sarah Differding; François-Xavier Hanin; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

6.  Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Yuko Goto; Megumi Jinguji; Sadao Tanaka; Yoshihiko Fukukura; Atsushi Tani; Michiyo Higashi
Journal:  Eur Radiol       Date:  2014-08-13       Impact factor: 5.315

Review 7.  Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Authors:  Stavroula Kyriazi; Stan B Kaye; Nandita M deSouza
Journal:  Nat Rev Clin Oncol       Date:  2010-04-13       Impact factor: 66.675

8.  Uptake decrease of proliferative PET tracer 18FLT in bone marrow after carbon ion therapy in lung cancer.

Authors:  Mitsuru Koizumi; Tsuneo Saga; Masayuki Inubushi; Toshimitsu Fukumura; Kyosan Yoshikawa; Naoyoshi Yamamoto; Mio Nakajima; Toshio Sugane; Masayuki Baba
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

9.  Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Michael A Deveau; Lyndsay Kubicek; Pamela White; Søren M Bentzen; Richard J Chappell; Lisa J Forrest; Robert Jeraj
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-15       Impact factor: 7.038

10.  Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.

Authors:  Matthew J Nyflot; Paul M Harari; Stephen Yip; Scott B Perlman; Robert Jeraj
Journal:  Radiother Oncol       Date:  2012-10-13       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.